The Evolution of Bioprocessing Reagents

Novel therapy development is focused on increasingly individualized and diverse solutions, requiring smaller, more customized batches of reagents and buffers to be used across the clinical pipeline as companies scale from process development to clinical trials and into commercialization. Existing bioprocessing infrastructure was not designed to manufacture these new drugs, forcing the industry to look for clinical-grade reagent formulations that are easily customizable, scalable, and efficiently produced. Teknova has been able to leverage their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies (ADCs and multispecifics) accelerate their breakthroughs to get into the clinic faster.  
 
Learn more about the importance of: 

- A manufacturing partner that offers speed, low minimum order size, and a wide range of custom options to enable scalable reagent production 

- A comprehensive quality management system designed to support custom GMP-grade reagent manufacturing 

- An experienced partner with inherent problem-solving skills who loves the challenge of a constantly evolving manufacturing environment